The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
DOPTELET (Swedish Orphan Biovitrum Pty Ltd)
Product name
DOPTELET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
248 (255 working days)
Active ingredients
avatrombopag maleate
Registration type
NCE/NBE
Indication
DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.